Interim report
Page 1
Note : This document has been translated from the Japanese original for reference purposes only . In the event of any discrepancy between this translated document and the Japanese original , the original shall prevail . FUJIFILM Financial Results ( Consolidated ) for the Three Months Ended June 30 , 2026 FUJIFILM Holdings Corporation Teiichi Goto President and Chief Executive Officer Projected date of the beginning of cash dividends : - Reference materials regarding operating results of the current quarter to be prepared : Yes Meeting to explain operating results of the current quarter to be held : Yes Accounting S Standards Fa FASF MEMBERSHIP August 6 , 2026 URL : https://holdings.fujifilm.com/en ( Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America . ) 1. Results of the Three Months Ended June 30 , 2026 ( From April 1 , 2026 to June 30 , 2026 ) ( 1 ) OPERATING RESULTS Amount Unit : Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen % : Changes from the corresponding period of the previous fiscal year Revenue Operating income Income before income taxes Net income attributable to FUJIFILM Holdings 1st Quarter ended June 30 , 2026 1st Quarter ended June 30 , 2025 Note : Comprehensive income 1st Quarter ended June 30 , 2026 826,493 749,482 % 10.3 % % % 0.1 51,184 75,291 ( 32.0 ) 21.1 52,100 71,954 ( 27.6 ) 37,424 ( 30.4 ) 0.3 53,767 ( 11.5 ) ¥ 88,782 million ( + 58.3 % ) 1st Quarter ended June 30 , 2025 ¥ 56,081 million ( -72.4 % ) 1st Quarter ended June 30 , 2026 1st Quarter ended June 30 , 2025 Net income attributable to FUJIFILM Holdings per share Net income attributable to FUJIFILM Holdings per share ( Assuming full dilution ) ( 2 ) FINANCIAL POSITION Total assets As of June 30 , 2026 As of March 31 , 2026 2. Cash Dividends Year ended March 31 , 2026 Year ending March 31 , 2027 Year ending March 31 , 2027 ( Forecast ) Yen 31.26 44.63 Yen 31.23 44.59 Amount Unit : Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen 6,167,301 6,053,776 Total equity ( Net asset ) 3,903,549 3,844,385 FUJIFILM Holdings shareholders ' equity ratio FUJIFILM Holdings shareholders ' equity to total assets % 3,898,484 3,839,550 63.2 63.4 Cash dividends per share 1st Quarter 2nd Quarter 3rd Quarter Year End Year Total Yen Yen Yen 35.00 Yen 35.00 Yen 70.00 37.50 37.50 75.00 Note : Changes in dividends forecast during the quarter under review : None 3. Forecast for the Fiscal Year Ending March 31 , 2027 ( From April 1 , 2026 to March 31 , 2027 ) Amount Unit : Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen % : Changes from the corresponding period of the previous fiscal year For the Year ending March 31 , 2027 Revenue Operating income Income before Net income attributable income taxes to FUJIFILM Holdings Net income attributable to FUJIFILM Holdings per share % 3,560,000 6.0 365,000 % 4.2 % 375,000 2.3 % 280,000 1.2 Yen 234.19 Note : Changes in forecast which was recently announced : Yes Note : The weighted - average number of shares used in calculating net income attributable to FUJIFILM Holdings shareholders per share is based on the number of shares outstanding as of June 30 , 2026 , excluding treasury shares .
Page 2
1. Issued (including treasury stock): As of June 30, 2026 1,234,150,284 As of March 31, 2026 1,243,877,184 2. Treasury stock: As of June 30, 2026 38,542,505 As of March 31, 2026 38,547,368 3. Average number of shares: 1st Quarter ended June 30, 2026 1,195,821,475 1st Quarter ended June 30, 2025 1,203,561,229 Notes (1) Significant changes in the scope of consolidation during the period: None (2) Adoption of simplified method of accounting or specific accounting treatments: None (3) Changes in accounting principles 1. Changes in accounting policies accompanied by revisions of accounting standards: None 2. Changes in accounting policies other than 1. above: None (4) Number of shares outstanding * Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None Explanation of Appropriate Use of Forecast and Other Special Items Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have an intention of guaranteeing the realization of the forecasts. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecasts and warnings for users of the forecasts are mentioned in the page 6, (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results in 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER.
Page 3
1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER …………………………………………………………………………………………………………… P.2 (1) Explanation on Consolidated Operating Results ………………………………………………... P.2 (2) Explanation on the Consolidated Financial Position ……………………………………………. P.5 (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results …… P.6 2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION ………………………………. P.7 (1) Significant Changes in the Scope of Consolidation During the Period ……………………….... P.7 (2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments …………... P.7 (3) Changes in Accounting Principles …………………………………………………………......... P.7 3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION .... P.7 4. CONSOLIDATED FINANCIAL STATEMENTS …………………………………………………….. P.8 (1) Consolidated Balance Sheets …………………………………………………………………… P.8 (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ... P.10 (Consolidated Statements of Income) …………………………………………………………... P.10 (Consolidated Statements of Comprehensive Income) …………………………………………. P.11 (3) Consolidated Statements of Cash Flows ………………………………………………………... P.12 (4) Notes to Consolidated Financial Statements ……………………………………………………. P.13 (Notes Relating to the Going Concern Assumption) ……………………………………………. P.13 (Segment Information) ………………………………………………………………………….. P.13 (Notes on Significant Changes to FUJIFILM Holdings Shareholders’ Equity)………………… P.15 (Significant Subsequent Events) ……………………………………………………………....... P.15 [INDEX] FUJIFILM Holdings Corporation (4901) 1
Page 4
Amount Unit: Billions of yen Three months ended June 30, 2026 Three months ended June 30, 2025 Change (Amount) Change (%) Domestic revenue 30.7% 253.7 34.3% 256.9 (3.1) (1.2%) Overseas revenue 69.3% 572.8 65.7% 492.6 80.2 16.3% Revenue 100.0% 826.5 100.0% 749.5 77.0 10.3% Operating income 6.2% 51.2 10.0% 75.3 (24.1) (32.0%) Income before income taxes 6.3% 52.1 9.6% 72.0 (19.9) (27.6%) Net income attributable to FUJIFILM Holdings 4.5% 37.4 7.2% 53.8 (16.3) (30.4%) Exchange rates (Yen / US$) ¥159 ¥145 ¥14 Exchange rates (Yen / Euro) ¥185 ¥164 ¥21 Revenue by Operating Segment Amount Unit: Billions of yen Segment Three months ended June 30, 2026 Three months ended June 30, 2025 Change (Amount) Change (%) Healthcare 256.8 228.5 28.4 12.4% Electronics 127.7 102.1 25.5 25.0% Business Innovation 273.2 273.6 (0.3) (0.1%) Imaging 168.8 145.3 23.5 16.2% Consolidated Total 826.5 749.5 77.0 10.3% Operating Income (Loss) by Operating Segment Amount Unit: Billions of yen Segment Three months ended June 30, 2026 Three months ended June 30, 2025 Change (Amount) Change (%) Healthcare (12.7) 4.3 (17.0) - Electronics 31.1 22.5 8.6 38.2% Business Innovation (1.4) 15.6 (17.0) - Imaging 43.4 41.8 1.6 3.9% Corporate Expenses etc. (9.2) (8.8) (0.4) - Consolidated Total 51.2 75.3 (24.1) (32.0%) 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER (1) Explanation on Consolidated Operating Results In the three months ended June 30, 2026, the Fujifilm Group recorded ¥826.5 billion in consolidated revenue (up 10.3% year-on-year) reflecting revenue increases in the Medical Systems, Semiconductor Materials and Imaging businesses. Operating income decreased to ¥51.2 billion (down 32.0% year-on-year), despite higher earnings in the Electronics and Imaging segments, primarily due to increased fixed costs in the Bio CDMO business in the Healthcare, one-time costs incurred to strengthen the organizational structure of Business Innovation segment, and the impact of rising raw material costs. Consolidated income before income taxes amounted to ¥52.1 billion (down 27.6% year-on-year), and consolidated net income attributable to FUJIFILM Holdings totaled ¥37.4 billion (down 30.4% year-on-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during the current quarter were ¥159 and ¥185, respectively. FUJIFILM Holdings Corporation (4901) 2
Page 5
Healthcare In the Healthcare segment, consolidated revenue amounted to ¥256.8 billion (up 12.4% year-on-year). Consolidated operating loss amounted to ¥12.7 billion. The Medical Systems business posted higher revenue. Sales of endoscopes continued to increase in key markets, including Japan, the U.S. and Europe. Medical IT sales also grew, with solid sales of systems and services, mainly for the SYNAPSE Picture Archiving and Communication System (PACS), in Japan, Europe and other markets, alongside sales of ultrasound diagnostic equipment, which experienced strong sales in Japan and Europe. In April 2026, we launched SYNAPSE LEAD Cloud, a cloud-based picture archiving and communication system, as a new addition to our PACS lineup. Moreover, in June 2026, we released the upper gastrointestinal scope EG-860Z and the lower gastrointestinal scopes EC-860ZP/M and EC-860ZP/L as a new lineup of magnifying endoscopes for ELUXEO, the endoscope system with LED light source. We will continue to leverage our proprietary technologies to provide a wide range of products and services that meet the various demands of medical settings, to contribute to further improving diagnostic efficiency, enhancing the quality of healthcare, and maintaining and promoting people’s health. Sales increased in the Bio CDMO business, driven by the expanding operations of the large-scale facilities at the North Carolina site in the U.S., which commenced operations in the previous fiscal year. In June 2026, we announced the co-development with HORIBA, Ltd. of a high-sensitivity inline Raman measurement system that enables real-time visualization of the cell culture and purification processes in biopharmaceutical manufacturing. Moving forward, we will proceed with verification for practical implementation and contribute to the stable production and reduction of manufacturing costs of high-quality biopharmaceuticals, including antibody drugs, through the visualization of manufacturing processes and the establishment of advanced data analysis technologies. The LS (Life Sciences) Solutions business *1 posted higher revenue due to the life sciences business delivering higher sales of culture media driven by increased usage by major pharmaceutical companies, alongside strong sales of iCell (iPS cell －derived differentiated cells) for drug discovery support backed by robust drug discovery needs, as well as the consumer healthcare business seeing strong sales of cosmetics. In May 2026, we opened the new U.S. headquarters in Wisconsin of FUJIFILM Cellular Dynamics, Inc., a leading company in the development and manufacturing of iPS cells. Through this, we will significantly enhance our manufacturing capacity for iPS cell- derived differentiated cells for drug discovery support, while also establishing cutting-edge laboratory facilities to support R&D in this field and process development for cell therapies, thereby supporting customers from the early stages of development. Furthermore, in May this year, we obtained manufacturing and marketing approval in Japan for the regenerative medical product SAVYSCUS ® Injection. This product is indicated for meniscal injuries for which meniscectomy is considered appropriate and is the first regenerative medical product approved in Japan *2 for meniscal injury. Through SAVYSCUS ® Injection , we aim to provide new treatment options for patients with meniscal injury and to contribute to improving and maintaining human health by offering a broad range of orthopedic solutions spanning prevention, diagnosis, and treatment. *1 The LS Solutions business comprises Life Sciences business, Pharmaceutical business, Consumer Healthcare business and CRO (Contract Research Organization) business. *2 The first regenerative medical product for meniscal injury to obtain manufacturing and marketing approval in Japan under the Pharmaceutical and Medical Device Act. Electronics In the Electronics segment, consolidated revenue amounted to ¥127.7 billion (up 25.0% year-on-year). Consolidated operating income amounted to ¥31.1 billion (up 38.2% year-on-year). In addition to the use of semiconductors in a wide range of products today such as smartphones, personal computers, automobiles and home appliances, the semiconductor market is now undergoing significant growth due to rising demand for AI semiconductors. By steadily capturing advanced materials demand for AI semiconductors, our Semiconductor Materials business achieved growth that significantly outpaced the market average in the previous fiscal year. Revenue increased substantially during the fiscal year under review, driven by sustained strong sales to major foundries alongside a recovery in sales to major semiconductor manufacturers in the U.S. and South Korea. By product, sales expanded for our copper interconnect CMP slurry and NTI developers, both of which hold the top global market share, as well as advanced photoresists, driven by miniaturization and the increasing number of interconnect layers. With respect to back-end materials, sales of liquid polyimide for interlayer insulation films used in inter-chip connections also increased, driven by expanding demand for advanced packaging for AI FUJIFILM Holdings Corporation (4901) 3
Page 6
semiconductors. In May 2026, we participated in ECTC 2026, an international conference on semiconductor packaging-related technologies. Aiming to achieve miniaturization in next-generation packaging to advance AI semiconductors, we presented the results of joint research conducted with imec, an international research institute for advanced semiconductors. Furthermore, we announced that we had newly developed a PFAS-free PBO (polybenzoxazole) insulating film material, thereby making all materials in the ZEMATES photosensitive insulating materials lineup PFAS-free. The AF (Advanced Functional) Materials business posted higher revenue due to strong sales of data tapes to major IT companies, amid increasing data volume associated with the widespread adoption of AI. In June 2026, we launched Round Prescale, a circular type designed to match semiconductor wafer shapes, as a new addition to our Prescale pressure measurement film lineup, designed for pressure inspection in semiconductor manufacturing processes. We will continue to contribute to improving and stabilizing customers’ manufacturing quality by developing and providing products that enable the streamlining of inspection operations in development and manufacturing sites. Business Innovation In the Business Innovation segment, consolidated revenue amounted to ¥273.2 billion (down 0.1% year-on-year). Consolidated operating loss amounted to ¥1.4 billion. The Business Solutions business posted higher revenue primarily due to solid performance in overseas ERP system sales and implementation support services, despite the absence of the temporary demand for BPO services overseas recorded in the same period of the previous fiscal year. In May 2026, we commenced the rollout of REiLI Business, an AI technology brand centered on digital technologies including AI, while also opening the REiLI Business Hub in Yokohama Minatomirai as a base for its implementation and value creation. With the aim of creating value closely aligned with real-world business operations, and in order to advance customers’ AI implementation more rapidly and reliably, this site will bring together experts in technology development, product planning and implementation to accelerate the value creation cycle by driving the entire process from ideation through verification to the commercialization of products and services. The Office Solutions business posted lower revenue mainly due to a decline in exports to Europe and the U.S. as well as lower sales in China. Revenue of the Graphic Communications business increased due to sales expansion of inkjet printheads in the inkjet field, among other factors. In June 2026, we announced the opening of the Revoria Experience Center, a new site in India responsible for high-value-added printing verification and human resource development. Through print output verification aimed at supporting diverse paper types and realizing high-value-added printed materials using special toners, as well as the training of operators and designers, we will contribute to expanding our customers’ businesses and improving their productivity in India’s growing printing market. Imaging In the Imaging segment, consolidated revenue amounted to ¥168.8 billion (up 16.2% year-on-year). Consolidated operating income amounted to ¥43.4 billion (up 3.9% year-on-year). The Consumer Imaging business posted higher revenue due to sales expansion of the instax instant photo systems. In addition to strong sales of mid-to-high-priced products—including instax mini Evo , which has maintained its popularity since its launch in 2021, and instax WIDE 400, which added a new color JET BLACK to its lineup this fiscal year—sales of film also expanded due to increased production capacity. In April 2026, we launched instax mini 13, an entry-level analog instant camera with renewed design and features, which has been well received globally. We will continue to expand the world of instax, enabling people to enjoy instant photo printing and further enhancing the value and joy of photography The Professional Imaging business posted higher revenue due to expanding sales of digital cameras, particularly in Asia where demand was robust. In addition to mainstay models launched in the previous fiscal year, such as FUJIFILM X-E5 and FUJIFILM X-T30 III, sales also trended strongly for FUJIFILM X100VI, a long-selling model that has maintained high popularity. We will continue to provide attractive products for digital camera users and the video production industry by delivering outstanding image quality through the large format sensors in the GFX series and achieving the best balance of image quality and size through the X series, while also creating cameras with new concepts, such as FUJIFILM GFX100RF, X half and FUJIFILM GFX ETERNA 55. FUJIFILM Holdings Corporation (4901) 4
Page 7
Amount Unit: Billions of yen Three months ended June 30, 2026 Three months ended June 30, 2025 Change Net cash provided by operating activities 92.3 94.8 (2.5) Net cash used in investing activities (124.9) (120.0) (4.9) Net cash provided by (used in) financing activities 6.3 20.1 (13.8) (2) Explanation on the Consolidated Financial Position At the end of the three months ended June 30, 2026, total assets increased by ¥113.5 billion compared with the end of the previous fiscal year (March 31, 2026) to ¥6,167.3 billion, mainly due to increases in property, plant and equipment and inventories. Total liabilities increased by ¥54.4 billion to ¥2,263.8 billion. FUJIFILM Holdings shareholders’ equity increased by ¥58.9 billion to ¥3,898.5 billion. The current ratio increased by 0.2 percentage points to 136.8%, the debt-equity ratio increased by 0.6 percentage points to 58.1%, and the equity ratio decreased by 0.2 percentage points to 63.2% compared with the end of the previous fiscal year. The Company is maintaining a stable level of asset liquidity and a sound capital structure. (Cash Flows) In the three months ended June 30, 2026, net cash provided by operating activities totaled ¥92.3 billion. Net cash used in investing activities amounted to ¥124.9 billion due to the acquisition of property, plants, equipment and other factors. As a result, free cash flow, or the sum of cash flow from operating and investing activities, was negative ¥32.6 billion. Net cash provided by financing activities amounted to ¥6.3 billion, due to an increase in long-term debt and other factors. As a result, cash and cash equivalents at the end of the three months ended on June 30, 2026 amounted to ¥150.7 billion, down ¥19.9 billion from the end of the previous fiscal year (March 31, 2026). FUJIFILM Holdings Corporation (4901) 5
Page 8
Amount Unit: Billions of yen Previous Forecast (A) (announced on May 12, 2026) Revised Forecast (B) Change (B-A) Change (%) (Reference) Actual Results for Fiscal Year ended March 31,2026 Revenue 3,470.0 3,560.0 90.0 2.6% 3,357.0 Operating income 365.0 365.0 - - 350.2 Income before income taxes 375.0 375.0 - - 366.6 Net income attributable to FUJIFILM Holdings 280.0 280.0 - - 276.7 Net income attributable to FUJIFILM Holdings per share ¥234.19 ¥234.19 ¥- - ¥229.65 ROE (%) 7.8 7.8 - - 7.7 ROIC (%) 5.6 5.6 - - 5.5 Exchange rates (Yen / US$) ¥150 ¥156 ¥6 - ¥151 Exchange rates (Yen / Euro) ¥175 ¥181 ¥6 - ¥175 (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results (Consolidated financial forecast for the fiscal year ending March 31, 2027) For the fiscal year ending March 31, 2027, the Company revised its consolidated revenue upward to ¥3,560.0 billion in consolidated revenue (up 2.6% from the previous forecast), reflecting factors such as strong sales in the Electronics as well as exchange rate fluctuations. Operating income is projected to remain unchanged from the previous forecast at ¥365.0 billion, because while sales increases in the Electronics and gains on the sale of non- core assets in the Business Innovation are expected, these will be offset by delayed profitability in the Bio CDMO business and the impact of rising semiconductor memory prices. Income before income taxes is expected to be ¥375.0 billion, and net income attributable to FUJIFILM Holdings is expected to be ¥280.0 billion. The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year ending March 31, 2027 are ¥156 and ¥181, respectively. FUJIFILM Holdings Corporation (4901) 6
Page 9
2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION (1) Significant Changes in the Scope of Consolidation During the Period: None. (2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments: None. (3) Changes in Accounting Principles: None. 3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION: None. FUJIFILM Holdings Corporation (4901) 7
Page 10
(1) Consolidated Balance Sheets Amount Unit: Millions of yen As of June 30, 2026 As of March 31, 2026 Change ASSETS Current assets: Cash and cash equivalents 150,651 170,553 (19,902) Notes and accounts receivable: Trade 686,793 742,721 (55,928) Lease receivables 31,479 31,750 (271) Affiliated companies 1,829 2,737 (908) Allowance for credit losses (13,624) (14,693) 1,069 706,477 762,515 (56,038) Inventories 667,065 600,796 66,269 Prepaid expenses and Other 195,584 185,169 10,415 Total current assets 1,719,777 1,719,033 744 Investments and long-term receivables: Investments in and advances to affiliated companies 37,555 37,617 (62) Investment securities 45,026 43,672 1,354 Long-term lease receivables 48,636 49,181 (545) Other long-term receivables 77,013 76,831 182 Allowance for credit losses (1,455) (1,511) 56 Total investments and long-term receivables 206,775 205,790 985 Property, plant and equipment: Land 121,864 121,419 445 Buildings and structures 1,208,813 1,173,654 35,159 Machinery, equipment and others 2,134,308 1,989,906 144,402 Construction in progress 914,292 979,735 (65,443) 4,379,277 4,264,714 114,563 Less accumulated depreciation (1,982,394) (1,956,406) (25,988) Total property, plant and equipment 2,396,883 2,308,308 88,575 Other assets: Operating lease right-of-use assets 133,238 130,157 3,081 Goodwill, net 1,006,314 997,068 9,246 Other intangible assets, net 148,998 151,175 (2,177) Other 555,316 542,245 13,071 Total other assets 1,843,866 1,820,645 23,221 Total assets 6,167,301 6,053,776 113,525 4. CONSOLIDATED FINANCIAL STATEMENTS FUJIFILM Holdings Corporation (4901) 8
Page 11
Amount Unit: Millions of yen As of June 30, 2026 As of March 31, 2026 Change LIABILITIES Current liabilities: Short-term debt 307,269 287,913 19,356 Notes and accounts receivable: Trade 314,656 291,296 23,360 Construction 82,487 97,154 (14,667) Affiliated companies 1,336 1,399 (63) 398,479 389,849 8,630 Accrued income taxes 33,333 53,202 (19,869) Accrued liabilities 291,609 280,017 11,592 Short-term operating lease liabilities 37,944 36,549 1,395 Other current liabilities 188,789 210,742 (21,953) Total current liabilities 1,257,423 1,258,272 (849) Non-current liabilities: Long-term debt 668,333 607,034 61,299 Accrued pension and severance costs 24,909 25,515 (606) Long-term operating lease liabilities 96,817 95,517 1,300 Other non-current liabilities 216,270 223,053 (6,783) Total non-current liabilities 1,006,329 951,119 55,210 Total liabilities 2,263,752 2,209,391 54,361 EQUITY FUJIFILM Holdings shareholders’ equity Capital 40,363 40,363 - Common stock, without par value: Authorized: 2,400,000,000 shares Issued: 1,234,150,284 shares Retained earnings 3,138,207 3,117,407 20,800 Accumulated other comprehensive income 787,288 736,167 51,121 Treasury stock, at cost (67,374) (54,387) (12,987) Total FUJIFILM Holdings shareholders’ equity 3,898,484 3,839,550 58,934 Noncontrolling interests 5,065 4,835 230 Total equity 3,903,549 3,844,385 59,164 Total liabilities and equity 6,167,301 6,053,776 113,525 As of June 30, 2026 As of March 31, 2026 Change Foreign currency translation adjustments 744,556 694,154 50,402 Pension liability adjustments 42,732 42,013 719 Note: Details of accumulated other comprehensive income (loss) FUJIFILM Holdings Corporation (4901) 9
Page 12
1st Quarter ended June 30 Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Amount % % % Revenue: 100.0 826,493 100.0 749,482 77,011 10.3 Cost of sales: 60.9 503,075 58.3 436,911 66,164 15.1 Gross profit 39.1 323,418 41.7 312,571 10,847 3.5 Operating expenses: Selling, general and administrative 27.8 229,949 26.2 196,643 33,306 16.9 Research and development 5.1 42,285 5.4 40,637 1,648 4.1 32.9 272,234 31.7 237,280 34,954 14.7 Operating income 6.2 51,184 10.0 75,291 (24,107) (32.0) Other income (expenses): Interest and dividend income 3,104 3,112 (8) Interest expense (1,859) (2,453) 594 Foreign exchange gains (losses), net (495) (5,984) 5,489 Gains (losses) on equity securities, net 1,978 (659) 2,637 Other, net (1,812) 2,647 (4,459) 0.1 916 (0.4) (3,337) 4,253 - Income before income taxes 6.3 52,100 9.6 71,954 (19,854) (27.6) Income taxes 1.8 15,154 2.8 20,829 (5,675) (27.2) Equity in net earnings of affiliated companies 0.1 630 0.4 2,698 (2,068) (76.6) Net income 4.5 37,576 7.2 53,823 (16,247) (30.2) Less: Net (income) loss attributable to the noncontrolling interests 0.0 (152) 0.0 (56) (96) - Net income attributable to FUJIFILM Holdings 4.5 37,424 7.2 53,767 (16,343) (30.4) (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income (Consolidated Statements of Income) FUJIFILM Holdings Corporation (4901) 10
Page 13
1st Quarter ended June 30 Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Net income 37,576 53,823 (16,247) Other comprehensive income (loss), net of tax: Foreign currency translation adjustments 50,487 2,429 48,058 Pension liability adjustments 719 (211) 930 Unrealized gains on derivatives - 40 (40) Total 51,206 2,258 48,948 Comprehensive income 88,782 56,081 32,701 Less: Comprehensive (income) loss attributable to noncontrolling interests (237) (128) (109) Comprehensive income attributable to FUJIFILM Holdings 88,545 55,953 32,592 (Consolidated Statements of Comprehensive Income) FUJIFILM Holdings Corporation (4901) 11
Page 14
(3) Consolidated Statements of Cash Flows Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Operating activities Net income 37,576 53,823 (16,247) Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 50,422 40,853 9,569 (Gains) losses on equity securities (1,978) 659 (2,637) Equity in net (gains) losses of affiliated companies, net of dividends received (152) (2,493) 2,341 Changes in operating assets and liabilities: Notes and accounts receivable 63,235 60,162 3,073 Inventories (60,021) (52,280) (7,741) Notes and accounts payable - trade 20,724 2,921 17,803 Changes in other current assets (8,203) (13,129) 4,926 Accrued income taxes and other liabilities (5,565) 4,916 (10,481) Others (3,745) (674) (3,071) Subtotal 54,717 40,935 13,782 Net cash provided by operating activities 92,293 94,758 (2,465) Investing activities Purchases of property, plant and equipment (107,794) (119,998) 12,204 Purchases of software (9,765) (9,993) 228 Sales of property, plant and equipment 1,686 － 1,686 Proceeds from sales and maturities of marketable and investment securities 786 2,365 (1,579) Purchases of marketable and investment securities (314) (595) 281 (Increase) decrease in time deposits, net (1,978) (1,350) (628) Increase in investments in and advances to affiliated companies － (81) 81 Acquisitions of businesses, net of cash acquired － (1,183) 1,183 Proceeds from sale of businesses, net of cash and cash equivalents disposed of － 6,926 (6,926) Others (7,522) 3,926 (11,448) Net cash used in investing activities (124,901) (119,983) (4,918) Financing activities Proceeds from long-term debt 100,000 100,000 0 Repayments of long-term debt (689) (40,616) 39,927 Increase (decrease) in short-term debt, net (20,816) 2,796 (23,612) Cash dividends paid to shareholders (42,187) (42,170) (17) Subsidiaries’ cash dividends paid to noncontrolling interests (7) (89) 82 Sales (purchase) of stock for treasury (30,002) (2) (30,000) Capital transactions with noncontrolling interests － 141 (141) Others 3 17 (14) Net cash provided by financing activities 6,302 20,077 (13,775) Effect of exchange rate changes on cash and cash equivalents 6,404 (6,991) 13,395 Net decrease in cash and cash equivalents (19,902) (12,139) (7,763) Cash and cash equivalents at beginning of period 170,553 172,111 (1,558) Cash and cash equivalents at end of period 150,651 159,972 (9,321) FUJIFILM Holdings Corporation (4901) 12
Page 15
(4) Notes to Consolidated Financial Statements (Note Relating to the Going Concern Assumption) None. a. Revenue Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Amount % Revenue: Composition (%) Composition (%) Healthcare 31.1 256,824 30.5 228,471 28,353 12.4 Electronics 15.4 127,650 13.6 102,140 25,510 25.0 Business Innovation 33.1 273,243 36.5 273,563 (320) (0.1) Imaging 20.4 168,776 19.4 145,308 23,468 16.2 Consolidated total 100.0 826,493 100.0 749,482 77,011 10.3 b. Expenses Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Amount % R&D expenses Healthcare 13,757 14,757 (1,000) (6.8) Electronics 8,079 7,022 1,057 15.1 Business Innovation 14,998 13,953 1,045 7.5 Imaging 4,264 3,010 1,254 41.7 Subtotal 41,098 38,742 2,356 6.1 Corporate 1,187 1,895 (708) (37.4) Consolidated total 42,285 40,637 1,648 4.1 Other operating expenses Healthcare 255,744 209,436 46,308 22.1 Electronics 88,443 72,595 15,848 21.8 Business Innovation 259,690 244,041 15,649 6.4 Imaging 121,119 100,529 20,590 20.5 Subtotal 724,996 626,601 98,395 15.7 Corporate 8,028 6,953 1,075 15.5 Consolidated total 733,024 633,554 99,470 15.7 c. Operating income Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Amount % Operating Income (Loss): Margin (%) Margin (%) Healthcare (4.9) (12,677) 1.9 4,278 (16,955) - Electronics 24.4 31,128 22.1 22,523 8,605 38.2 Business Innovation (0.5) (1,445) 5.7 15,569 (17,014) - Imaging 25.7 43,393 28.7 41,769 1,624 3.9 Total 60,399 84,139 (23,740) (28.2) Corporate expenses etc. (9,215) (8,848) (367) - Consolidated total 6.2 51,184 10.0 75,291 (24,107) (32.0) (Segment Information) FUJIFILM Holdings Corporation (4901) 13
Page 16
Healthcare: Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc. Electronics: Semiconductor materials, display materials, industrial equipment, fine chemicals, etc. Business Innovation: Solutions and services, digital MFPs, equipment and materials for graphic communications, inks and industrial inkjet printheads, etc. Imaging: Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc. d. Total Assets Amount Unit: Millions of yen As of June 30, 2026 As of March 31, 2026 Change Amount % Total assets: Healthcare 3,300,741 3,227,034 73,707 2.3 Electronics 826,360 821,265 5,095 0.6 Business Innovation 1,440,496 1,469,229 (28,733) (2.0) Imaging 477,057 423,126 53,931 12.7 Subtotal 6,044,654 5,940,654 104,000 1.8 Corporate 122,647 113,122 9,525 8.4 Consolidated total 6,167,301 6,053,776 113,525 1.9 e. Depreciation and amortization, and Capital expenditures Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Amount % Depreciation and amortization: Healthcare 24,027 17,178 6,849 39.9 Electronics 7,738 7,346 392 5.3 Business Innovation 12,664 11,516 1,148 10.0 Imaging 4,802 3,708 1,094 29.5 Corporate 1,191 1,105 86 7.8 Consolidated total 50,422 40,853 9,569 23.4 Capital expenditures: Healthcare 82,928 109,104 (26,176) (24.0) Electronics 5,863 5,006 857 17.1 Business Innovation 12,973 12,417 556 4.5 Imaging 7,282 2,956 4,326 146.3 Corporate 2,134 939 1,195 127.3 Consolidated total 111,180 130,422 (19,242) (14.8) Note: The major products and services of each operating segment are as follows: FUJIFILM Holdings Corporation (4901) 14
Page 17
f. Overseas revenue (Destination Base) Amount Unit: Millions of yen Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026 Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025 Change Amount % Revenue: Composition (%) Composition (%) Domestic 30.7 253,728 34.3 256,872 (3,144) (1.2) Overseas: The Americas 21.2 175,266 20.7 155,321 19,945 12.8 Europe 18.0 148,443 16.6 124,559 23,884 19.2 Asia and others 30.1 249,056 28.4 212,730 36,326 17.1 Subtotal 69.3 572,765 65.7 492,610 80,155 16.3 Consolidated total 100.0 826,493 100.0 749,482 77,011 10.3 Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer’s location. (Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity) None. (Significant Subsequent Events) None. FUJIFILM Holdings Corporation (4901) 15